NDAORALSUSPENSION, EXTENDED RELEASE
Approved
Mar 2013
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
4/8 — Partial
KARBINAL ER (carbinoxamine maleate) by Aytu BioPharma is 12. First approved in 2013.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KARBINAL ER is an extended-release oral suspension of carbinoxamine maleate, a first-generation H1 receptor antagonist indicated for allergic rhinitis and related allergic conditions. It works by competing with histamine for receptor sites on effector cells, providing anticholinergic and sedative properties with sustained plasma levels over 12 hours.
Peak2.9 years to LOE
Product is at peak lifecycle stage with moderate competitive pressure (score 8/10), indicating stable but defended market position with established field teams.
Mechanism of Action
12.1 Mechanism of Action Carbinoxamine is an H1 receptor antagonist (antihistamine) that exhibits anticholinergic (drying) and sedative properties. Antihistamines compete with histamine for receptor sites on effector cells. 12.3 Pharmacokinetics Carbinoxamine Maleate extended-release oral…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Worked on KARBINAL ER at Aytu BioPharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.